Guru Sonpavde1, Mingjun Wang2, Leif E Peterson3, Helen Y Wang2, Teresa Joe4, Martha P Mims5, Dov Kadmon6, Michael M Ittmann7, Thomas M Wheeler8, Adrian P Gee9, Rong-Fu Wang2, Teresa G Hayes1. 1. Department of Medicine, Section of Medical Oncology, Baylor College of Medicine, Houston, TX, USA; Michael E. DeBakey Veterans Affairs Medical Center, VA 111H, 2002 Holcombe Blvd, Houston, TX 77030, USA. 2. Center for Inflammation and Epigenetics, The Methodist Hospital Research Institute and Weill Cornell Medical College of Cornell University, 6670 Bertner Street, Houston, TX 77030, USA. 3. Center for Biostatistics, The Methodist Hospital Research Institute and Weill Cornell Medical College of Cornell University, Houston, TX, USA. 4. Michael E. DeBakey Veterans Affairs Medical Center, VA 111H, 2002 Holcombe Blvd, Houston, TX 77030, USA. 5. Department of Medicine, Section of Medical Oncology, Baylor College of Medicine, Houston, TX, USA. 6. Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA. 7. Michael E. DeBakey Veterans Affairs Medical Center, VA 111H, 2002 Holcombe Blvd, Houston, TX 77030, USA; Department of Pathology, Baylor College of Medicine, Houston, TX, USA. 8. Department of Pathology, Baylor College of Medicine, Houston, TX, USA. 9. Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA.
Abstract
BACKGROUND: Given the immunogenicity of NY-ESO-1 peptides in prostate cancer, a phase I clinical trial was designed to evaluate HLA class-I and class-II restricted NY-ESO-1 peptides in metastatic castration-resistant prostate cancer (mCRPC). METHODS: Patients with progressive mCRPC, Zubrod Performance Status ≤2, PSA ≥10 ng/ml who had appropriate HLA class I (A2) and class II haplotypes (DR4, DP4) were eligible. Three groups with 3 patients each received the vaccine subcutaneously every 2 weeks for 6 doses. Group 1 received a peptide presented by an HLA class I haplotype (HLA-A2), Group 2 with a peptide presented by HLA class II haplotype (DR4, DP4), and Group 3 with peptides presented by both Class I and II haplotypes. Androgen-deprivation was continued. Owing to a myocardial infarction, the protocol was amended to omit the use of GM-CSF. RESULTS: Fourteen patients were evaluable for toxicities and 9 received all 6 doses and were evaluable for efficacy. One death from myocardial infarction following GM-CSF occurred in a patient with generalized myalgias. After omitting GM-CSF, no grade >2 toxicities were observed. Among 9 patients evaluable for efficacy, the median PSA doubling time pre-therapy and during therapy were 3.1 and 4.92 months, respectively. NY-ESO-1 specific T-cell response observed by ELISPOT appeared more frequent in docetaxel-naïve patients (4 of 4) than docetaxel-pretreated patients (2 of 5). CONCLUSION: In men with mCRPC, individualized HLA class-I and/or class-II restricted NY-ESO-1 peptides were tolerable, appeared to slow PSA doubling time and yielded antigen-specific T-cell responses more often in chemonaïve patients.
BACKGROUND: Given the immunogenicity of NY-ESO-1 peptides in prostate cancer, a phase I clinical trial was designed to evaluate HLA class-I and class-II restricted NY-ESO-1 peptides in metastatic castration-resistant prostate cancer (mCRPC). METHODS:Patients with progressive mCRPC, Zubrod Performance Status ≤2, PSA ≥10 ng/ml who had appropriate HLA class I (A2) and class II haplotypes (DR4, DP4) were eligible. Three groups with 3 patients each received the vaccine subcutaneously every 2 weeks for 6 doses. Group 1 received a peptide presented by an HLA class I haplotype (HLA-A2), Group 2 with a peptide presented by HLA class II haplotype (DR4, DP4), and Group 3 with peptides presented by both Class I and II haplotypes. Androgen-deprivation was continued. Owing to a myocardial infarction, the protocol was amended to omit the use of GM-CSF. RESULTS: Fourteen patients were evaluable for toxicities and 9 received all 6 doses and were evaluable for efficacy. One death from myocardial infarction following GM-CSF occurred in a patient with generalized myalgias. After omitting GM-CSF, no grade >2 toxicities were observed. Among 9 patients evaluable for efficacy, the median PSA doubling time pre-therapy and during therapy were 3.1 and 4.92 months, respectively. NY-ESO-1 specific T-cell response observed by ELISPOT appeared more frequent in docetaxel-naïve patients (4 of 4) than docetaxel-pretreated patients (2 of 5). CONCLUSION: In men with mCRPC, individualized HLA class-I and/or class-II restricted NY-ESO-1 peptides were tolerable, appeared to slow PSA doubling time and yielded antigen-specific T-cell responses more often in chemonaïve patients.
Authors: E Jäger; S Gnjatic; Y Nagata; E Stockert; D Jäger; J Karbach; A Neumann; J Rieckenberg; Y T Chen; G Ritter; E Hoffman; M Arand; L J Old; A Knuth Journal: Proc Natl Acad Sci U S A Date: 2000-10-24 Impact factor: 11.205
Authors: L Muderspach; S Wilczynski; L Roman; L Bade; J Felix; L A Small; W M Kast; G Fascio; V Marty; J Weber Journal: Clin Cancer Res Date: 2000-09 Impact factor: 12.531
Authors: Elke Jäger; Julia Karbach; Sacha Gnjatic; Antje Neumann; Armin Bender; Danila Valmori; Maha Ayyoub; Erika Ritter; Gerd Ritter; Dirk Jäger; Dennis Panicali; Eric Hoffman; Linda Pan; Herbert Oettgen; Lloyd J Old; Alexander Knuth Journal: Proc Natl Acad Sci U S A Date: 2006-09-19 Impact factor: 11.205
Authors: E Jäger; Y Nagata; S Gnjatic; H Wada; E Stockert; J Karbach; P R Dunbar; S Y Lee; A Jungbluth; D Jäger; M Arand; G Ritter; V Cerundolo; B Dupont; Y T Chen; L J Old; A Knuth Journal: Proc Natl Acad Sci U S A Date: 2000-04-25 Impact factor: 11.205
Authors: Philip M Arlen; Fernando Bianco; William L Dahut; Anthony D'Amico; William D Figg; Stephen J Freedland; James L Gulley; Philip W Kantoff; Michael W Kattan; Andrew Lee; Meredith M Regan; Oliver Sartor Journal: J Urol Date: 2008-04-18 Impact factor: 7.450
Authors: Axel Hoos; Alexander M M Eggermont; Sylvia Janetzki; F Stephen Hodi; Ramy Ibrahim; Aparna Anderson; Rachel Humphrey; Brent Blumenstein; Lloyd Old; Jedd Wolchok Journal: J Natl Cancer Inst Date: 2010-09-08 Impact factor: 13.506
Authors: Faviel F Gonzalez-Galarza; Stephen Christmas; Derek Middleton; Andrew R Jones Journal: Nucleic Acids Res Date: 2010-11-09 Impact factor: 16.971
Authors: E Jäger; D Jäger; J Karbach; Y T Chen; G Ritter; Y Nagata; S Gnjatic; E Stockert; M Arand; L J Old; A Knuth Journal: J Exp Med Date: 2000-02-21 Impact factor: 14.307
Authors: Eleftheria A Anastasopoulou; Ioannis F Voutsas; Michael Papamichail; Constantin N Baxevanis; Sonia A Perez Journal: Oncoimmunology Date: 2016-05-02 Impact factor: 8.110
Authors: Harm Westdorp; Annette E Sköld; Berit A Snijer; Sebastian Franik; Sasja F Mulder; Pierre P Major; Ronan Foley; Winald R Gerritsen; I Jolanda M de Vries Journal: Front Immunol Date: 2014-05-06 Impact factor: 7.561